Norman B. Chutkan, MD, FACS (University of Arizona College of Medicine and The CORE Institute), Michael J. Vives, MD (Rutgers University, New Jersey Medical School) and F. Todd Wetzel, MD (Temple University School of Medicine) address complications.

Disclosures:

Chutkan, Norman B.: Royalties: Globus Medical (D); Speaking and/or Teaching Arrangements: AO North America (Nonfinancial, Travel Expense Reimbursement); Board of Directors: NASS (Travel Expense Reimbursement).

Vives, Michael J.: Private Investments: Accelalox (less than 1%), CreOsso (8%), NOC2  (less than 1%); Other Office: AAOS (Nonfinancial, Spine Content Committee), NASS (Nonfinancial, Spine Journal Advisory Editorial Board), J of Spinal Cord Medicine (Nonfinancial, Associate Editor); Grants: National Science Foundation (F, Paid directly to institution/employer), North American Spine Society (D, Paid directly to institution/employer).

Wetzel, F. Todd: Stock Ownership: Relievant Medical (less than 1%).

Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+